NaPro BioTherapeutics

NaPro BioTherapeutics was a biopharmaceutical company specializing in the development and production of complex natural product-based pharmaceuticals, most notably the cancer drug paclitaxel. The company developed a proprietary semi-synthetic process for producing paclitaxel from the needles of the yew tree, providing a sustainable alternative to traditional bark-based extraction. This technology led to significant supply agreements with major firms like Abbott Laboratories and a high-profile legal settlement with Bristol-Myers Squibb regarding market exclusivity. Following its success in the taxane market, the company shifted its focus to a proprietary pipeline of next-generation oncology agents designed to overcome drug resistance. In 2004, the company rebranded as Tapestry Pharmaceuticals to reflect this strategic evolution toward drug discovery and development. Despite advancing several candidates into clinical trials, the company eventually faced financial challenges and filed for bankruptcy in 2009.